期刊文献+

康莱特注射液联合吉非替尼治疗EGFR阳性中晚期非小细胞肺癌的临床观察 被引量:3

Clinical Observation of Kanglaite Injection Combined with Gefitinib in the Treatment of Non-small Cell Lung Cancer with EGFR Positive in Medium or Late Stage
原文传递
导出
摘要 目的:研究康莱特注射液联合吉非替尼治疗EGFR阳性中晚期非小细胞肺癌的疗效。方法:将45例中晚期非小细胞肺癌患者随机分为联合靶向组及单纯靶向组,联合靶向组采用康莱特注射液联合吉非替尼口服治疗,单纯靶向组采用吉非替尼口服治疗,观察两个疗程后评价疗效。结果:联合靶向组总有效率56.0%,高于单纯靶向组的40.0%(P〈0.05);在生活质量方面,联合靶向组的总有效率84.0%,高于单纯靶向组的60.0%(P〈0.05)。结论:康莱特注射液联合吉非替尼治疗EGFR阳性中晚期非小细胞肺癌的疗效优于单纯口服吉非替尼,同时生活质量明显改善,是,临床治疗EGFR阳性中晚期非小细胞肺癌有效的治疗方法。 Objective: Study on effect of Kanglaite injection combined with Gefitinib in the treatment of nonsmall cell lung cancer with EGFR positive in medium or late stage. Methods: 45 cases of medium and advanced nosmall cell lung cancer were randomly divided into combined target group and simple target group, combined target group was given Kanglaite injection combined with Ge fitinib PO, while simple targeting group given Gefitinib PO, for evaluation of curative effect after two courses. Results: Total effec tive rate of combined target group was 56% ,higher than the simple targeted group of 40% (P〈0.05); In terms of life quality, total ef fective rate of combined target group was 84%, higher than the targeted group of 60% (P〈0.05). Conclusion: the curative effect of Kanglaite injection combined with Kyrgyzstan in the treatment of medium and advanced nonsmall cell lung cancer with EGFR posi tive is better than Gefitinib PO , at the same time, improved quality of life, is the effective clinical treatment for medium and ad vanced nonsmall cell lung cancer with EGFR positive.
出处 《按摩与康复医学》 2013年第4期76-78,共3页 Chinese Manipulation and Rehabilitation Medicine
关键词 非小细胞肺癌 EGFR 康莱特 吉非替尼 non-small cell lung cancer EGFR Kanglaite Injection(KLT) Gefitinib
  • 相关文献

参考文献4

  • 1Herbst RS, Maddox AM, Rothenberg ML, et al. Selective oral epi- dermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well tolerated and has activity in non small cell lung cancer and other solid tumors: results of a phase I trial[J].J Clin Oncol,2002,20(18):3 815-3 825.
  • 2Herbst RS. Dose comparative monotherapy trials of ZD1839 in previously treated non small cell lung cancer patients[J].Semin Oncol,2003,30(1):30-38.
  • 3Cella D. Impact of ZD1839 on non-small cell lung cancer related symptoms as measured by the functional assessment of cancer therapy lung scale[J].Semin Oncol,2003,30( 1):39-48.
  • 4王晓东,李妍延.康莱特注射液治疗胰腺癌研究进展[J].现代肿瘤医学,2007,15(9):1351-1352. 被引量:8

二级参考文献14

共引文献7

同被引文献50

引证文献3

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部